JVM Reports Solid Q1 2026: Revenue KRW 45.5B, OP KRW 9.3B

Consolidated revenue KRW 45.48B, OP KRW 9.29B, net income KRW 7.59B (EPS KRW 658)
Debt ratio 39.33% (slight increase from 36.41% at year-end 2025)
Cash & equivalents + short-term financial products: KRW 140.68B, solid financial position
Quarterly R&D spend KRW 2.19B (4.8% of sales); three new products expected to complete development in H1 2026
High reliance on related parties (Onlienpharm, Hanmi Pharmaceutical); consistent dividend payments (2025 payout ratio 26.4%)
[Risk]Loss in lawsuit against NH Investment & Securities (KRW 1B) finalized; JVM Europe B.V. remains negative equity (-KRW 6.49B)